Main navigation

Srinivasan (Vasan) Yegnasubramanain

Department Affiliations Oncology, SOM, Environmental Health Services, SPH
Rank Associate Professor
Office Phone 410-502-3425
Lab Phone 410-614-2676
SOM Address 145 CRB II

Christopher Weier 2009 – 2015

Roo Steinberg 2015


Research Interests

The Yegnasubramanian lab is focused on understanding the complex interplay between genetic and epigenetic alterations in carcinogenesis and disease progression, and on exploiting this understanding in developing novel biomarkers for diagnosis and risk stratification as well as in identifying targets for therapeutic intervention. As part of a larger team with the laboratories of William G. Nelson and Angelo M. De Marzo, we use approaches along the entire spectrum of basic to translational research to tackle challenges in cancer research in a multidisciplinary fashion. We have charted four broad categories of investigation: i) understanding the complex interplay of genetic and epigenetic processes in cancer initiation and progression; ii) targeting epigenetic alterations for biomarker development and cancer therapy; iii) understanding the role of genome organization and topoisomerases in androgen signaling, transcription, and genomic instability and using this understanding to develop novel biomarkers and therapies; iv) development of genomics technologies for correlative and functional cancer research


Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, Isaacs WB, Bova GS, Liu W, Xu J, Meeker AK, Netto G, De Marzo AM, Nelson WG, Yegnasubramanian S. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet. 2010 Aug;42(8):668-75. PMCID: PMC3157086


Aryee MJ, Liu W, Engelmann JC, Nuhn P, Gurel M, Haffner MC, Esopi D, Irizarry RA, Getzenberg RH, Nelson WG, Luo J, Xu J, Isaacs WB, Bova GS, Yegnasubramanian S. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med. 2013 Jan 23;5(169):169ra10. PMCID: PMC3577373


Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, Adejola N, Gürel M, Hicks J, Meeker AK, Halushka MK, Simons JW, Isaacs WB, De Marzo AM, Nelson WG, Yegnasubramanian S. Tracking the clonal origin of lethal prostate cancer. J Clin Invest. 2013 Nov;123(11):4918-22. PMCID: PMC3809798


Weier C, Haffner MC, Mosbruger T, Esopi DM, Hicks J, Zheng Q, Fedor H, Isaacs WB, De Marzo AM, Nelson WG, Yegnasubramanian S. Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer. J Pathol. 2013 Jun;230(2):174-83. PMCID: PMC3668093


Haffner MC, Chaux A, Meeker AK, Esopi DM, Gerber J, Pellakuru LG, Toubaji A, Argani P, Iacobuzio-Donahue C, Nelson WG, Netto GJ, De Marzo AM, Yegnasubramanian S. Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget. 2011 Aug;2(8):627-37. PMCID: PMC3248214


Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson WG. Hypermethylation of CpG islands in primary and metastatic human prostate cancer.  Cancer Res. 2004 Mar 15;64(6):1975-86. PMID: 15026333


Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z, Irizarry RA, Morgan J, Hicks J, DeWeese TL, Isaacs WB, Bova GS, De Marzo AM, Nelson WG. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res. 2008 Nov 1;68(21):8954-67. PMCID: PMC2577392